Skip to main content

ADVERTISEMENT

Efthymios N. Deliargyris, MD

08/01/2008
Over the past decade clinical trials have demonstrated that platelet glycoprotein (GP) IIb/IIIa receptor inhibition dramatically reduces the ischemic complications of percutaneous coronary intervention (PCI).1–6 Currently, there are 3...
Over the past decade clinical trials have demonstrated that platelet glycoprotein (GP) IIb/IIIa receptor inhibition dramatically reduces the ischemic complications of percutaneous coronary intervention (PCI).1–6 Currently, there are 3...
Over the past decade clinical...
08/01/2008
Journal of Invasive Cardiology
08/01/2008
Case report. A 49-year-old white female presented with recurrent angina. Six months prior, she was successfully treated for a similar anginal syndrome with a 5.0 x 43 Magic Wallstent in the proximal and mid-RCA. Coronary angiography showed a...
Case report. A 49-year-old white female presented with recurrent angina. Six months prior, she was successfully treated for a similar anginal syndrome with a 5.0 x 43 Magic Wallstent in the proximal and mid-RCA. Coronary angiography showed a...
Case report. A 49-year-old white...
08/01/2008
Journal of Invasive Cardiology
08/01/2008
Percutaneous coronary intervention (PCI) is increasingly used in patients with high-risk baseline characteristics.1–4 A prior stroke may identify patients who are at higher risk for post-PCI complications. However, no comparative data exist...
Percutaneous coronary intervention (PCI) is increasingly used in patients with high-risk baseline characteristics.1–4 A prior stroke may identify patients who are at higher risk for post-PCI complications. However, no comparative data exist...
Percutaneous coronary...
08/01/2008
Journal of Invasive Cardiology